{ "id": "R42130", "type": "CRS Report", "typeId": "REPORTS", "number": "R42130", "active": true, "source": "EveryCRSReport.com, University of North Texas Libraries Government Documents Department", "versions": [ { "source": "EveryCRSReport.com", "id": 455802, "date": "2016-09-14", "retrieved": "2016-10-17T19:28:30.988186", "title": "FDA Regulation of Medical Devices", "summary": "Prior to and since the passage of the Medical Device Amendments of 1976, Congress has debated how best to ensure that consumers have access, as quickly as possible, to new and improved medical devices and, at the same time, prevent devices that are not safe and effective from entering or remaining on the market. Medical device regulation is complex, in part, because of the wide variety of items that are categorized as medical devices; examples range from a simple tongue depressor to a life-sustaining heart valve. The regulation of medical devices can affect their cost, quality, and availability in the health care system.\nIn order to be legally marketed in the United States, many medical devices must be reviewed by the Food and Drug Administration (FDA), the agency responsible for protecting the public health by overseeing medical products. FDA\u2019s Center for Devices and Radiological Health (CDRH) is primarily responsible for medical device review. CDRH activities are funded by congressional appropriations and user fees collected from device manufacturers, which together comprise the program level budget. User fees account for 43% of FDA\u2019s total FY2016 program level and 28% of CDRH\u2019s FY2016 program level. The CDRH program level budget in FY2016 is $450 million, including $127 million in user fees. FDA\u2019s authority to collect medical device user fees, originally authorized in 2002 (P.L. 107-250), has been reauthorized in five-year increments and was reauthorized through FY2017 in the FDA Safety and Innovation Act (FDASIA, P.L. 112-144). \nUnder the Federal Food, Drug, and Cosmetic Act (FFDCA), all medical device manufacturers must register their facilities and list their devices with FDA and follow general controls requirements. FDA classifies devices according to the risk they pose to consumers. The FFDCA requires premarket review for moderate- and high-risk devices. There are two main paths that manufacturers can use to bring such devices to market. One path consists of conducting clinical studies and submitting a premarket approval (PMA) application that includes evidence providing reasonable assurance that the device is safe and effective. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process results in FDA clearance and tends to be much less expensive and less time-consuming than seeking FDA approval via PMA. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device. Demonstrating substantial equivalence does not usually require submitting clinical data demonstrating safety and effectiveness. Once its device is approved or cleared for marketing, a manufacturer must comply with regulations on manufacturing, labeling, surveillance, device tracking, and adverse event reporting. In 2015, FDA approved 98% of PMAs accepted for review and 85% of 510(k)s accepted for review were determined to be substantially equivalent.\nProblems related to medical devices can have serious consequences for consumers. Defects in medical devices, such as artificial hips and pacemakers, have caused severe patient injuries and deaths. Reports published in 2009 through 2011\u2014by the Government Accountability Office (GAO), the Department of Health and Human Services Office of the Inspector General, and the Institute of Medicine\u2014have voiced concerns about FDA\u2019s device review process. In 2009, 2011, 2013, and 2015 FDA\u2019s oversight of medical products was included on the GAO list of high-risk areas. In response to these concerns, FDA has conducted internal reviews and has implemented changes, including plans for a new National Evaluation System for health Technology (NEST).", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "http://www.crs.gov/Reports/R42130", "sha1": "e264de5e030f9b2a905e1c15930f52d8756c0829", "filename": "files/20160914_R42130_e264de5e030f9b2a905e1c15930f52d8756c0829.html", "images": null }, { "format": "PDF", "encoding": null, "url": "http://www.crs.gov/Reports/pdf/R42130", "sha1": "ae8301780dc499c18adfc49fa991996c399c95ab", "filename": "files/20160914_R42130_ae8301780dc499c18adfc49fa991996c399c95ab.pdf", "images": null } ], "topics": [ { "source": "IBCList", "id": 4806, "name": "Manufacturing Policy" }, { "source": "IBCList", "id": 4880, "name": "FDA Product Regulation & Medical Research" } ] }, { "source": "EveryCRSReport.com", "id": 453248, "date": "2016-06-08", "retrieved": "2016-06-21T21:06:05.612819", "title": "FDA Regulation of Medical Devices", "summary": "Prior to and since the passage of the Medical Device Amendments of 1976, Congress has debated how best to ensure that consumers have access, as quickly as possible, to new and improved medical devices and, at the same time, prevent devices that are not safe and effective from entering or remaining on the market. Medical device regulation is complex, in part, because of the wide variety of items that are categorized as medical devices; examples range from a simple tongue depressor to a life-sustaining heart valve. The regulation of medical devices can affect their cost, quality, and availability in the health care system.\nIn order to be legally marketed in the United States, many medical devices must be reviewed by the Food and Drug Administration (FDA), the agency responsible for protecting the public health by overseeing medical products. FDA\u2019s Center for Devices and Radiological Health (CDRH) is primarily responsible for medical device review. CDRH activities are funded by congressional appropriations and user fees collected from device manufacturers, which together comprise the program level budget. User fees account for 43% of FDA\u2019s total FY2016 program level and 28% of CDRH\u2019s FY2016 program level. The CDRH program level budget in FY2016 is $450 million, including $127 million in user fees. FDA\u2019s authority to collect medical device user fees, originally authorized in 2002 (P.L. 107-250), has been reauthorized in five-year increments and was reauthorized through FY2017 in the FDA Safety and Innovation Act (FDASIA, P.L. 112-144). \nUnder the Federal Food, Drug, and Cosmetic Act (FFDCA), all medical device manufacturers must register their facilities and list their devices with FDA and follow general controls requirements. FDA classifies devices according to the risk they pose to consumers. The FFDCA requires premarket review for moderate- and high-risk devices. There are two main paths that manufacturers can use to bring such devices to market. One path consists of conducting clinical studies and submitting a premarket approval (PMA) application that includes evidence providing reasonable assurance that the device is safe and effective. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process results in FDA clearance and tends to be much less expensive and less time-consuming than seeking FDA approval via PMA. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device. Demonstrating substantial equivalence does not usually require submitting clinical data demonstrating safety and effectiveness. Once its device is approved or cleared for marketing, a manufacturer must comply with regulations on manufacturing, labeling, surveillance, device tracking, and adverse event reporting. In 2015, FDA approved 98% of PMAs accepted for review and 85% of 510(k)s accepted for review were determined to be substantially equivalent.\nProblems related to medical devices can have serious consequences for consumers. Defects in medical devices, such as artificial hips and pacemakers, have caused severe patient injuries and deaths. Reports published in 2009 through 2011\u2014by the Government Accountability Office (GAO), the Department of Health and Human Services Office of the Inspector General, and the Institute of Medicine\u2014have voiced concerns about FDA\u2019s device review process. In 2009, 2011, 2013, and 2015 FDA\u2019s oversight of medical products was included on the GAO list of high-risk areas. In response to these concerns, FDA has conducted internal reviews and has implemented changes, including plans for a new National Evaluation System for health Technology (NEST).", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "http://www.crs.gov/Reports/R42130", "sha1": "890c72060875b966c51f464cbcc279ad402ee992", "filename": "files/20160608_R42130_890c72060875b966c51f464cbcc279ad402ee992.html", "images": null }, { "format": "PDF", "encoding": null, "url": "http://www.crs.gov/Reports/pdf/R42130", "sha1": "34d68f81f256f27f8049325e5d59d6659b9a4603", "filename": "files/20160608_R42130_34d68f81f256f27f8049325e5d59d6659b9a4603.pdf", "images": null } ], "topics": [ { "source": "IBCList", "id": 2678, "name": "Medical Product Regulation" }, { "source": "IBCList", "id": 4070, "name": "Health Care Delivery" }, { "source": "IBCList", "id": 4602, "name": "Manufacturing Policy" } ] }, { "source": "EveryCRSReport.com", "id": 452040, "date": "2016-04-26", "retrieved": "2016-05-24T19:17:09.085941", "title": "FDA Regulation of Medical Devices", "summary": "Prior to and since the passage of the Medical Device Amendments of 1976, Congress has debated how best to ensure that consumers have access, as quickly as possible, to new and improved medical devices and, at the same time, prevent devices that are not safe and effective from entering or remaining on the market. Medical device regulation is complex, in part, because of the wide variety of items that are categorized as medical devices; examples range from a simple tongue depressor to a life-sustaining heart valve. The regulation of medical devices can affect their cost, quality, and availability in the health care system.\nIn order to be legally marketed in the United States, many medical devices must be reviewed by the Food and Drug Administration (FDA), the agency responsible for protecting the public health by overseeing medical products. FDA\u2019s Center for Devices and Radiological Health (CDRH) is primarily responsible for medical device review. CDRH activities are funded by congressional appropriations and user fees collected from device manufacturers, which together comprise the program level budget. User fees account for 43% of FDA\u2019s total FY2016 program level and 28% of CDRH\u2019s FY2016 program level. The CDRH program level budget in FY2016 is $450 million, including $127 million in user fees. FDA\u2019s authority to collect medical device user fees, originally authorized in 2002 (P.L. 107-250), has been reauthorized in five-year increments and was reauthorized through FY2017 in the FDA Safety and Innovation Act (FDASIA, P.L. 112-144). FDASIA also reauthorized the prescription drug user fee program, created new user fee programs for generic and biosimilar drug approvals, and modified FDA authority to regulate medical products including medical devices.\nUnder the Federal Food, Drug, and Cosmetic Act (FFDCA), all medical device manufacturers must register their facilities and list their devices with FDA and follow general controls requirements. FDA classifies devices according to the risk they pose to consumers. The FFDCA requires premarket review for moderate- and high-risk devices. There are two main paths that manufacturers can use to bring such devices to market. One path consists of conducting clinical studies and submitting a premarket approval (PMA) application that includes evidence providing reasonable assurance that the device is safe and effective. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process results in FDA clearance and tends to be much less expensive and less time-consuming than seeking FDA approval via PMA. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device. Demonstrating substantial equivalence does not usually require submitting clinical data demonstrating safety and effectiveness. Once its device is approved or cleared for marketing, a manufacturer must comply with regulations on manufacturing, labeling, surveillance, device tracking, and adverse event reporting.\nProblems related to medical devices can have serious consequences for consumers. Defects in medical devices, such as artificial hips and pacemakers, have caused severe patient injuries and deaths. Reports published in 2009 through 2011\u2014by the Government Accountability Office (GAO), the Department of Health and Human Services Office of the Inspector General, and the Institute of Medicine\u2014have voiced concerns about FDA\u2019s device review process. In 2009, 2011, 2013, and 2015 FDA\u2019s oversight of medical products was included on the GAO list of high-risk areas. In response to these concerns, FDA has conducted internal reviews and has implemented changes.", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "http://www.crs.gov/Reports/R42130", "sha1": "40be6fc5e5d96448ae8fd9edafd1767f3b442805", "filename": "files/20160426_R42130_40be6fc5e5d96448ae8fd9edafd1767f3b442805.html", "images": null }, { "format": "PDF", "encoding": null, "url": "http://www.crs.gov/Reports/pdf/R42130", "sha1": "a71de1dc372bb8cccb5a8205902c88c74dc16395", "filename": "files/20160426_R42130_a71de1dc372bb8cccb5a8205902c88c74dc16395.pdf", "images": null } ], "topics": [ { "source": "IBCList", "id": 2678, "name": "Medical Product Regulation" }, { "source": "IBCList", "id": 4070, "name": "Health Care Delivery" }, { "source": "IBCList", "id": 4602, "name": "Manufacturing Policy" } ] }, { "source": "EveryCRSReport.com", "id": 418734, "date": "2013-02-12", "retrieved": "2016-04-06T21:22:54.917195", "title": "FDA Regulation of Medical Devices", "summary": "Prior to and since the passage of the Medical Device Amendments of 1976, Congress has debated how best to ensure that consumers have access, as quickly as possible, to new and improved medical devices and, at the same time, prevent devices that are not safe and effective from entering or remaining on the market. Medical devices regulation is complex, in part, because of the wide variety of items that are categorized as medical devices; examples range from a simple tongue depressor to a life-sustaining heart valve. The regulation of medical devices can affect their cost, quality, and availability in the health care system.\nIn order to be legally marketed in the United States, many medical devices must be reviewed by the Food and Drug Administration (FDA), the agency responsible for protecting the public health by overseeing medical products. FDA\u2019s Center for Devices and Radiological Health (CDRH) is primarily responsible for medical device review. CDRH activities are funded through a combination of public money (i.e., direct FDA appropriations from Congress) and private money (i.e., user fees collected from device manufacturers) which together comprise FDA\u2019s total. User fees accounted for 35% of FDA\u2019s total FY2012 program level and 14% of CDRH\u2019s program level, which was $376 million in FY2012 including $53 million in user fees. FDA\u2019s authority to collect user fees, originally authorized in 2002 (P.L. 107-250), has been reauthorized in five-year increments and was reauthorized through FY2017 via Title II of the FDA Safety and Innovation Act (FDASIA, P.L. 112-144). FDASIA also reauthorized the prescription drug user fee program, created new user fee programs for generic and biosimilar drug approvals, and modified FDA authority to regulate medical products including medical devices.\nAll medical product manufacturers are required to register their facilities and list their devices with FDA and follow general controls requirements. FDA classifies devices according to the risk they pose to consumers. Premarket review is required for moderate- and high-risk devices. There are two paths that manufacturers can use to bring such devices to market. One path consists of conducting clinical studies, submitting a premarket approval (PMA) application, and requires evidence providing reasonable assurance that the device is safe and effective. The other path involves submitting a 510(k) notification demonstrating that the device is substantially equivalent to a device already on the market (a predicate device) that does not require a PMA. The 510(k) process results in FDA clearance and tends to be much less expensive and less time-consuming than seeking FDA approval via PMA. Substantial equivalence is determined by comparing the performance characteristics of a new device with those of a predicate device; clinical data demonstrating safety and effectiveness are usually not required. Once approved or cleared for marketing, manufacturers must comply with regulations on manufacturing, labeling, surveillance, device tracking, and adverse event reporting.\nProblems related to medical devices can have serious consequences for consumers. Defects in medical devices, such as artificial hips and pacemakers, have caused severe patient injuries and deaths. In 2006, FDA reported 116,086 device-related injuries, 96,485 malfunctions, and 2,830 deaths; an analysis by the National Research Center for Women & Families claims there were 4,556 device-related deaths in 2009. Reports published in 2009 through 2011\u2014by the Government Accountability Office (GAO), the Department of Health and Human Services Office of the Inspector General and the Institute of Medicine\u2014have voiced concerns about FDA\u2019s device review process. In 2009, 2011, and 2013, FDA\u2019s oversight of medical products was included on the GAO list of high-risk areas. FDA has conducted internal reviews and is implementing changes.", "type": "CRS Report", "typeId": "REPORTS", "active": true, "formats": [ { "format": "HTML", "encoding": "utf-8", "url": "http://www.crs.gov/Reports/R42130", "sha1": "12076178f69d149f68c5ed15c2383b770b9818cd", "filename": "files/20130212_R42130_12076178f69d149f68c5ed15c2383b770b9818cd.html", "images": null }, { "format": "PDF", "encoding": null, "url": "http://www.crs.gov/Reports/pdf/R42130", "sha1": "22bfb307ed41d32c6789d3b4bac91cbfdcfecc98", "filename": "files/20130212_R42130_22bfb307ed41d32c6789d3b4bac91cbfdcfecc98.pdf", "images": null } ], "topics": [ { "source": "IBCList", "id": 2678, "name": "Medical Product Regulation" }, { "source": "IBCList", "id": 4070, "name": "Health Care Delivery" }, { "source": "IBCList", "id": 4602, "name": "Manufacturing Policy" } ] }, { "source": "University of North Texas Libraries Government Documents Department", "sourceLink": "https://digital.library.unt.edu/ark:/67531/metadc810729/", "id": "R42130_2012Jun25", "date": "2012-06-25", "retrieved": "2016-03-19T13:57:26", "title": "FDA Regulation of Medical Devices", "summary": null, "type": "CRS Report", "typeId": "REPORT", "active": false, "formats": [ { "format": "PDF", "filename": "files/20120625_R42130_6ee7ca461152476e016d7e02e275e16703585f9e.pdf" }, { "format": "HTML", "filename": "files/20120625_R42130_6ee7ca461152476e016d7e02e275e16703585f9e.html" } ], "topics": [] } ], "topics": [ "Appropriations", "Health Policy" ] }